In conclusion, the potential anti-cancer activity of metformin is based on two principal aspects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact tumor cell proliferation; second, its direct influence on the many pro-cancer signaling pathways regulated by PI3K/AKT/mTOR, which are key drivers of BC aggressiveness. This evidence concerns the gene INS and breast cancer.